



## FEP Medical Policy Manual

### FEP 2.04.79 Genetic Testing for Alpha-1 Antitrypsin Deficiency

---

**Annual Effective Policy Date: April 1, 2024**

**Original Policy Date: September 2012**

**Related Policies:**

None

---

## Genetic Testing for Alpha-1 Antitrypsin Deficiency

### Description

#### Description

Alpha<sub>1</sub>-antitrypsin deficiency (AATD) is an autosomal recessive genetic disorder that results in decreased production of functional alpha<sub>1</sub>-antitrypsin (AAT) protein or production of abnormal types of the protein that are functionally deficient. Individuals with AATD, especially smokers, have an increased risk of lung and liver disease. Available tests measure serum AAT levels and phenotype AAT protein variants. Genetic testing is also available to detect the most common pathogenic variants associated with AATD.

#### OBJECTIVE

The objective of this evidence review is to determine whether genetic testing for alpha<sub>1</sub>-antitrypsin deficiency in patients with suspected alpha<sub>1</sub>-antitrypsin deficiency (AATD) deficiency improves the net health outcomes compared with standard care without genetic testing.

## POLICY STATEMENT

Genetic testing for alpha<sub>1</sub>-antitrypsin deficiency may be considered **medically necessary** when either of the following conditions are met:

1. Individual is suspected of having alpha<sub>1</sub>-antitrypsin deficiency because of clinical factors and/or because the individual may be at high risk of having alpha<sub>1</sub>-antitrypsin deficiency due to a first-degree relative with alpha<sub>1</sub>-antitrypsin deficiency (see Policy Guidelines section); OR
2. Individual has a serum alpha<sub>1</sub>-antitrypsin level in the range of severe deficiency (see Policy Guidelines section).

Genetic testing for alpha<sub>1</sub>-antitrypsin deficiency is considered **investigational** in all other situations.

## POLICY GUIDELINES

Clinical factors relevant for suspicion of alpha<sub>1</sub>-antitrypsin deficiency based on 2016 COPD Foundation clinical practice guidelines are :

- Individuals with chronic obstructive pulmonary disease (COPD);
- Individuals with asthma and airflow obstruction not completely reversible with bronchodilators;
- Individuals with otherwise unexplained liver disease;
- Individuals with necrotizing panniculitis;
- Individuals with anti-proteinase 3-positive vasculitis (cytoplasmic anti-neutrophil cytoplasmic antibody-positive vasculitis);
- Individuals with bronchiectasis without evident etiology.

Family history relevant for suspicion of alpha<sub>1</sub>-antitrypsin deficiency:

- A first-degree relative is defined as a parent, child, or sibling.

Table PG1 shows the range of serum levels of alpha<sub>1</sub>-antitrypsin by common phenotypes according to the commercial standard milligram per deciliter and the purified standard micromole. A level less than 11 mmol is generally considered to be associated with an increased risk of clinical disease, but this cutoff may vary by the specific test used (American Thoracic Society & European Respiratory Society, 2003; Global Initiative for Chronic Obstructive Lung Disease, 2023).

**Table PG1. Range of Alpha1-Antitrypsin Serum Levels by Common Phenotypes**

	MM	MZ	SS	SZ	ZZ	Znull	Null-Null
mmol	20-48	17-33	15-33	8-16	2.5-7	<2.5	0
mg/dL	150-350	90-210	100-200	75-120	20-45	<20	0

## Genetics Nomenclature Update

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (see Table PG2). The Society's nomenclature is recommended by the Human Variome Project, the HUman Genome Organization, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG3 shows the recommended standard terminology-"pathogenic," "likely pathogenic," "uncertain significance," "likely benign," and "benign"-to describe variants identified that cause Mendelian disorders.

**Table PG2. Nomenclature to Report on Variants Found in DNA**

Previous	Updated	Definition
Mutation	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

**Table PG3. ACMG-AMP Standards and Guidelines for Variant Classification**

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

## Genetic Counseling

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

## BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

Screening (other than the preventive services listed in the brochure) is not covered. Please see Section 6 General exclusions.

Benefits are available for specialized diagnostic genetic testing when it is medically necessary to diagnose and/or manage a patient's existing medical condition. Benefits are not provided for genetic panels when some or all of the tests included in the panel are not covered, are experimental or investigational, or are not medically necessary.

## FDA REGULATORY STATUS

In 2007, the phenotyping test Hydragel 18 A1AT ISOFOCUSING kit (Sebia, GA) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for the qualitative detection and identification of the phenotypes of AAT protein. In 2022, the SPIFE A1AT phenotyping kit (Helena Laboratories) was approved by the FDA by the 510(k) process for the same indication. In 2017, the A1AT Genotyping Test (Grifols) was approved by the FDA as an aid to diagnosis of individuals with AATD. FDA product code: OBZ, PZH.

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the FDA has chosen not to require any regulatory review of this test.

## RATIONALE

### Summary of Evidence

For individuals who have suspected alpha<sub>1</sub>-antitrypsin deficiency (AATD) who receive genetic testing for AATD, the evidence includes studies on clinical validity, and several controlled studies assessing potential clinical utility. Relevant outcomes are test accuracy and validity, symptoms, and morbid events. Genetic testing can confirm a diagnosis of AATD suggested by serum testing by identifying the known genetic variants associated with the disease and identify AATD when a diagnosis is uncertain due to the suspicious clinical presentation that is not confirmed by serum testing. A chain of evidence suggests that making a diagnosis of AATD in individuals with suspected AATD can support clinical utility by allowing monitoring for multisystem complications and initiation of accepted therapies. Knowledge of AATD status may lead to behavior changes or changes in medical management that lead to improved health outcomes. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

## SUPPLEMENTAL INFORMATION

### Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in "Supplemental Information" if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

#### Canadian Thoracic Society

In 2012, the Canadian Thoracic Society published clinical practice guidelines on alpha<sub>1</sub>-antitrypsin deficiency (AATD) testing and alpha<sub>1</sub>-antitrypsin (AAT) augmentation therapy.<sup>22</sup> The recommendations for targeted testing for AATD included:

- Targeted testing for AATD may be considered in those individuals with chronic obstructive pulmonary disease (COPD) who were either diagnosed before 65 years of age or who had less than a 20 pack-year history of smoking.
- Targeted testing for AATD was not recommended in individuals with bronchiectasis or asthma.

#### American Thoracic Society and European Respiratory Society

In 2003, the American Thoracic Society and European Respiratory Society published joint recommendations on the diagnosis and management of individuals with AATD.<sup>1</sup> Table 1 summarizes the relevant recommendations.

**Table 1. Recommendations for Diagnosis and Management of Alpha-1 Antitrypsin Deficiency**

Recommendations for Diagnostic Testing	GOR <sup>a</sup>
<ul style="list-style-type: none"> <li>"Symptomatic adults with emphysema, chronic obstructive pulmonary disease (COPD), or asthma with airflow obstruction that is not completely reversible with aggressive treatment with bronchodilators...."</li> <li>"Individuals with unexplained liver disease..."</li> <li>"Asymptomatic individuals with persistent obstruction on pulmonary function tests with identifiable risk factors (eg, cigarette smoking, occupational exposure)"</li> <li>"Adults with necrotizing panniculitis..."</li> <li>"Siblings of an individual with known AAT deficiency"</li> </ul>	A
<ul style="list-style-type: none"> <li>"Adults with bronchiectasis without evidence etiology"</li> <li>"Adolescents with persistent airflow obstruction"</li> <li>"Asymptomatic individuals with persistent airflow obstruction and no risk factors"</li> <li>"Adults with C-ANCA-positive (anti-proteinase 3-positive) vasculitis"</li> <li>"Individuals with a family history of COPD or liver disease not known to be attributed to AAT deficiency"</li> <li>"Distant relatives of an individual who is homozygous for AAT deficiency"</li> <li>"Offspring or parents of an individual with homozygous AAT deficiency"</li> <li>"Siblings, offspring, parents, or distant relatives of an individual who is heterozygous for AAT deficiency"</li> <li>"Individuals at high risk of having AAT deficiency-related diseases"</li> <li>"Individuals who are not at risk themselves of having AAT deficiency but who are partners of individuals who are homozygous or heterozygous for AAT deficiency"</li> </ul>	B
<ul style="list-style-type: none"> <li>"Adults with asthma in whom airflow obstruction is completely reversible"</li> <li>"Predispositional testing"</li> <li>"Population screening of smokers with normal spirometry"</li> </ul>	C
<ul style="list-style-type: none"> <li>"Predispositional fetal testing"</li> <li>"Population screening of either neonates, adolescents, or adults"<sup>b</sup></li> </ul>	D

AAT: alpha1-antitrypsin; C-ANCA: cytoplasmic anti-neutrophil cytoplasmic antibodies; COPD: chronic obstructive pulmonary disease; GOR grade of recommendation.

<sup>a</sup> Type A: genetic testing is recommended;

type B: genetic testing should be discussed and could be accepted or declined; type C: genetic testing is not recommended (ie, should not be encouraged); type D: recommend against genetic testing (ie, should be discouraged).

<sup>b</sup> Population screening is not recommended currently. However, a possible exception (type B recommendation) may apply in countries satisfying all 3 of the following conditions: (1) the prevalence of AAT deficiency is high (about 1/1500, or more); (2) smoking is prevalent; and (3) adequate counseling services are available.

## European Respiratory Society

In 2017, the European Respiratory Society published an updated statement on the diagnosis and treatment of pulmonary disease with AATD.<sup>23</sup> Statements relating to genetic testing include:

- Quantitative determination of AAT levels is the crucial first step in identifying AATD, which must be supported by qualitative tests to identify the genetic mutation(s) causing AATD.
- Protein phenotyping by isoelectric focusing identifies variants where AAT is present, including the rare variants F, I, and P etc.
- Genotyping allows a rapid and precise identification/exclusion of S and Z alleles and other variants, where specific primers are available.

- Gene sequencing remains necessary for cases where a null variant or a deficient variant other than Z or S is suspected.
- Testing of relatives of identified patients should be considered after appropriate counseling.

## World Health Organization

A 1997 memorandum, published by the World Health Organization following a 1996 meeting on AATD, included the following recommendations relevant to this review<sup>24</sup>:

- "[A]ll patients with COPD and adults and adolescents with asthma [should] be screened once for AAT deficiency using a quantitative test. Those with abnormal results on screening should undergo PI [protease inhibitor] typing."
- "[N]eonatal AAT screening programmes should be undertaken in all developed countries with Caucasian populations." Among research needs listed is an "Analysis of the costs and benefits of screening, as a prelude to implementing neonatal screening for AAT deficiency."
- "There is an urgent need for randomized clinical trials of the efficacy of AAT augmentation therapy in persons with the deficiency."

## U.S. Preventive Services Task Force Recommendations

Not applicable.

## Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

## REFERENCES

1. American Thoracic Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. *Am J Respir Crit Care Med*. Oct 01 2003; 168(7): 818-900. PMID 14522813
2. Kelly E, Greene CM, Carroll TP, et al. Alpha-1 antitrypsin deficiency. *Respir Med*. Jun 2010; 104(6): 763-72. PMID 20303723
3. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. *N Engl J Med*. Jun 10 1976; 294(24): 1316-21. PMID 1083485
4. Stoller JK, Lacbawan FL, Aboussouan LS. Alpha-1 antitrypsin deficiency. In: Adam M, Ardinger H, Pagon R, et al., eds. *GeneReviews*. Seattle, WA: University of Washington; 2017.
5. CSL Behring LLC. Zemaira, Alpha1-Proteinase Inhibitor (Human): Package Insert. 2022 Sep; <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c3354b5-a1d8-4f98-ad55-2eafe4265c4e>. Accessed November 28, 2022.
6. Baxter Healthcare Corp. GLASSIA (Alpha1-Proteinase Inhibitor (Human)): Package Insert. 2022 Mar; <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83473cbb-48e4-42a2-81b6-4c851423da7b>. Accessed November 28, 2022.
7. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management, and Prevention of COPD 2023. 2023; <https://goldcopd.org/2023-gold-report-2/>. Accessed November 28, 2022.
8. Food and Drug Administration (FDA). 510(k) substantial equivalence determination decision summary (K063498). n.d.; [http://www.accessdata.fda.gov/cdrh\\_docs/reviews/K063498.pdf](http://www.accessdata.fda.gov/cdrh_docs/reviews/K063498.pdf). Accessed November 28, 2022.
9. Greulich T, Averyanov A, Borsa L, et al. European screening for alpha 1 -antitrypsin deficiency in subjects with lung disease. *Clin Respir J*. Jan 2017; 11(1): 90-97. PMID 25919395
10. Sorroche PB, Fernandez Acquier M, Lopez Jove O, et al. Alpha-1 Antitrypsin Deficiency in COPD Patients: A Cross-Sectional Study. *Arch Bronconeumol*. Nov 2015; 51(11): 539-43. PMID 25800328
11. Ljujic M, Topic A, Divac A, et al. Isoelectric focusing phenotyping and denaturing gradient gel electrophoresis genotyping: a comparison of two methods in detection of alpha-1-antitrypsin variants. *Transl Res*. May 2008; 151(5): 255-9. PMID 18433707
12. Beletic A, Dudvarski-Ilic A, Milenkovic B, et al. Is an integrative laboratory algorithm more effective in detecting alpha-1-antitrypsin deficiency in patients with premature chronic obstructive pulmonary disease than AAT concentration based screening approach?. *Biochem Med (Zagreb)*. 2014; 24(2): 293-8. PMID 24969923
13. Lopez-Campos JL, Osaba L, Czischke K, et al. Feasibility of a genotyping system for the diagnosis of alpha1 antitrypsin deficiency: a multinational cross-sectional analysis. *Respir Res*. Jun 10 2022; 23(1): 152. PMID 35689213
14. Lerman C, Gold K, Audrain J, et al. Incorporating biomarkers of exposure and genetic susceptibility into smoking cessation treatment: effects on smoking-related cognitions, emotions, and behavior change. *Health Psychol*. Jan 1997; 16(1): 87-99. PMID 9028818
15. Audrain J, Boyd NR, Roth J, et al. Genetic susceptibility testing in smoking-cessation treatment: one-year outcomes of a randomized trial. *Addict Behav*. 1997; 22(6): 741-51. PMID 9426791



16. Carpenter MJ, Strange C, Jones Y, et al. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. *Ann Behav Med.* Feb 2007; 33(1): 22-8. PMID 17291167
17. Ashenurst JR, Nhan H, Shelton JF, et al. Prevalence of Alpha-1 Antitrypsin Deficiency, Self-Reported Behavior Change, and Health Care Engagement Among Direct-to-Consumer Recipients of a Personalized Genetic Risk Report. *Chest.* Feb 2022; 161(2): 373-381. PMID 34656525
18. Gtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. *Cochrane Database Syst Rev.* Sep 20 2016; 9(9): CD007851. PMID 27644166
19. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. *Am J Respir Crit Care Med.* Nov 1999; 160(5 Pt 1): 1468-72. PMID 10556107
20. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. *Eur Respir J.* Jun 2009; 33(6): 1345-53. PMID 19196813
21. Chapman KR, Burdon JG, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe  $\alpha$ 1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. *Lancet.* Jul 25 2015; 386(9991): 360-8. PMID 26026936
22. Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. *Can Respir J.* 2012; 19(2): 109-16. PMID 22536580
23. Miravittles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in  $\alpha$  1 - antitrypsin deficiency. *Eur Respir J.* Nov 2017; 50(5). PMID 29191952
24. Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. *Bull World Health Organ.* 1997; 75(5): 397-415. PMID 9447774

## POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
September 2012	New policy	
June 2013	Replace policy	Policy updated with literature search, no change to policy statement.
June 2014	Replace Policy	Policy updated with literature review. No references added. No change to policy statements.
June 2015	Replace Policy	Policy updated with literature review. Reference 9 added. Policy statements unchanged.
March 2018	Replace Policy	Policy updated with literature review through November 6, 2017; reference 3, 4, 8, 9, 14-17, and 19 added. Policy statements unchanged except "not medically necessary" wording corrected to "investigational: due to CLIA testing.
March 2019	Replace Policy	Policy updated with literature review through November 6, 2017; reference 9 added; reference 4 updated. Policy statements unchanged.
September 2019	Replace Policy	Edits made to Policy Section and Table PG1 Updated; family history language removed from first medically necessary statement due to brochure genetic benefit language
March 2020	Replace Policy	Policy updated with literature review through November 11, 2019; no references added. Policy statements unchanged.
March 2021	Replace policy	Policy updated with literature review through October 19, 2020; no references added. Policy statements unchanged.
March 2022	Replace policy	Policy updated with literature review through October 18, 2021; no references added. Policy statements unchanged.
March 2023	Replace policy	Policy updated with literature review through November 28, 2022; references added. Minor editorial refinements to policy statements; intent unchanged. FEP added 2 conditions to the policy statement: Airflow obstruction which is not completely reversible with bronchodilators. Persistent obstruction without identifiable risk factors.
March 2023	Replace policy	Policy updated with literature review through November 28, 2022; references added. Minor editorial refinements to policy statements; intent unchanged. Off cycle review September 2023 Policy Guidelines section updated; intent unchanged. No edits to policy statements
March 2024	Replace policy - off-cycle update	Policy Guidelines section updated; intent unchanged. No edits to policy statements.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.